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From the perspective of health care 
practitioners, the most useful clinical 
trials are those that assess the effective-
ness of a drug, that is, determine how 
well the drug works under conditions 
of actual clinical practice. Clinical tri-
als designed to determine effectiveness 
should use outcome measures that have 
the greatest clinical significance for prac-
titioners, with the goal of maximizing 
generalizability and addressing practi-
cal questions about the risks, benefits, 
and costs of an intervention in routine 
clinical practice (1). Here we would like 
to emphasize the importance of social 
functioning and quality of life (QOL) 
as outcome variables in clinical trials in 
patients with schizophrenia. 
Recent research has shown that atyp-
ical antipsychotics improve QOL in pa-
tients with schizophrenia (2). However, 
studies that incorporate QOL in the as-
sessment of long-term effectiveness are 
limited and inconsistent. Fleischhacker 
and Goodwin summarize the results 
of the Cost Utility of the Latest Antip-
sychotic Drugs in Schizophrenia Study 
(CUtLASS) (3), which employed the 
Quality of Life Scale (4) as the primary 
outcome measure for evaluating the ef-
fectiveness of treatment. The CUtLASS 
found no disadvantage of first-gener-
ation antipsychotics in comparison to 
non-clozapine second-generation antip-
sychotics. Similarly, in a double-blind, 
randomized controlled trial, Rosenheck 
et al (5) reported that measures of effec-
tiveness demonstrated no advantage for 
olanzapine compared with haloperidol 
in overall QOL. In contrast, a natural-
istic observational study on patients 
with schizophrenia undergoing usual 
care indicated that ziprasidone treat-
ment resulted in improved satisfaction 
with general activity as measured by the 
Quality of Life Enjoyment and Satisfac-
tion Questionnaire (6).
When measuring QOL in patients 
taking antipsychotics, it is important 
to acknowledge that a variety of factors 
may influence QOL outcomes: these 
include side effects and daily dosage of 
the antipsychotic, depressive and nega-
tive symptoms, duration of treatment, 
and subjective tolerability. In a natural-
istic comparative study, Ritsner et al (7) 
found no significant difference in gen-
eral QOL between patients using atypi-
cal vs. typical antipsychotics. However, 
after adjusting for daily dosage, duration 
of treatment, and subjective tolerability, 
QOL measures indicated that atypical 
antipsychotics (olanzapine and risperi-
done) were superior to typical ones. 
Some randomized controlled trials of 
antipsychotics have used a social func-
tioning scale as an outcome measure, 
such as the Social and Occupational 
Functioning Assessment Scale (8,9), the 
Medical Outcomes Study Short-Form 
36 Health Survey (10), or the Personal 
and Social Performance scale (PSP) 
(11). However, these trials have largely 
involved short-term interventions, lim-
iting their ability to detect meaningful 
changes in the social functioning of pa-
tients. We are currently undertaking a 
randomized, controlled, open-label clin-
ical trial in Korea to evaluate improve-
ment in social functioning in patients 
with schizophrenia or schizoaffective 
disorder. The study compares long-act-
ing injectable vs. oral risperidone using a 
hybrid model to assess both efficacy and 
effectiveness after one year of treatment. 
Primary outcome measures in this study 
are the PSP and the Social Functioning 
Scale. 
The scales used to assess social func-
tioning and QOL in clinical trials must 
be appropriate to the study population 
and the clinical condition, and should 
measure several dimensions of social 
functioning and QOL. Furthermore, 
we need to develop scales that measure 
functioning independently from symp-
toms, and that are sensitive to changes 
over the course of the illness. 
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